Karolinska researchers develop method to measure extent to which drugs reach their targets
Could contribute to the development of new and improved drug substances
Researchers at Karolinska Institutet in Sweden have developed what they believe to be the first method for directly measuring the extent to which drugs reach their targets in cells. The method, which is described in the journal Science, could make a significant contribution to the development of new, improved drug substances.
Most drugs operate by binding to one or more proteins and affecting their function, which creates two common bottlenecks in their development: identifying the right target proteins; and designing drug molecules able efficiently to seek out and bind to them. No method has been available so far for directly measuring the efficiency of drug molecules locating and binding to their target protein.
The researchers have now developed a new tool called CETSA (Cellular Thermal Shift Assay), which uses the concept that target proteins are usually stabilised when drug molecules bind.
‘We have shown that the method works on a wide variety of target proteins and allows us to directly measure whether the drug molecules reach their targets in cells and animal models,’ says lead investigator Professor Pär Nordlund of the Department of Medical Biochemistry and Biophysics. ‘We believe that CETSA will eventually help to improve the efficiency of many drugs and contribute to better drug molecules and more successful treatments.’
We have shown that the method works on a wide variety of target proteins and allows us to directly measure whether the drug molecules reach their targets in cells and animal models
The lack of methods to directly measure the binding of a drug to its target protein has caused a degree of uncertainty in many phases of drug development. In some cases, where drug candidates have not lived up to expectations in clinical trials on humans, it has transpired that the drug molecules have failed to bind to the right protein. The group behind the study believes that CETSA will be an important control stage and complement other methods.
The researchers also examined processes that can lead to drug resistance in cells. They believe that by virtue of its ability to determine whether existing drugs are suitable for individual patients, the method is of potential value to the development of personalised medicines.
‘We believe that the method can provide an important diagnostic tool in the treatment of cancer, for example, as CETSA can, in principle, enable us to determine which drug is most effective at targeting the proteins in the tumour,’ says Daniel Martinez Molina at the Department of Medical Biochemistry and Biophysics, who leads a team in the project aiming at establishing CETSA for patient studies.
‘This also makes it possible for clinicians to ascertain at an early stage of treatment whether the tumour has developed a certain kind of resistance and which type of therapy could then be more suitable for the patient.’
